Stockscreener 앱 받기
105.91
7.96%
7.805
시간 외 거래:
106.06
0.155
+0.15%
전일 마감가:
$98.10
열려 있는:
$98.85
하루 거래량:
135.95K
Relative Volume:
2.28
시가총액:
$3.37B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-90.19
EPS:
-1.1742
순현금흐름:
-
1주 성능:
+14.10%
1개월 성능:
+43.11%
6개월 성능:
+72.26%
1년 성능:
+58.99%
1일 변동 폭
$97.98
$107.00
1주일 범위
$90.77
$107.00
52주 변동 폭
$49.00
$107.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
105.91 | 3.42B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of... - markets.businessinsider.com
Belite Bio Announces UK’s Medicines and Healthcare Products - GlobeNewswire
Belite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Belite Bio stock hits all-time high at 101.92 USD By Investing.com - Investing.com Australia
Belite Bio stock hits all-time high at 101.92 USD - Investing.com
Can machine learning forecast Belite Bio Inc Depositary Receipt recoveryIndex Update & Consistent Growth Equity Picks - newser.com
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
How Belite Bio Inc Depositary Receipt stock performs during Fed tightening cyclesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
Belite Bio to Present at the dbVICDeutsche Bank ADR Virtual Investor Conference November 4th - GlobeNewswire
Belite Bio (NASDAQ: BLTE) to present 10:30 ET at ADR Virtual Investor Conf.; 90-day replay - Stock Titan
How Belite Bio Inc (Common Stock) (D01) stock valuation compares with sectorJuly 2025 Update & Reliable Entry Point Trade Alerts - fcp.pa.gov.br
Risk vs reward if holding onto Belite Bio Inc Depositary ReceiptJuly 2025 Breakouts & Free Verified High Yield Trade Plans - newser.com
Why Belite Bio Inc Depositary Receipt stock could benefit from AI revolution2025 Sector Review & Daily Oversold Bounce Ideas - newser.com
Belite Bio (NASDAQ:BLTE) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will Belite Bio Inc (Common Stock) (D01) stock outperform energy sector in 2025Earnings Trend Report & Stepwise Entry and Exit Trade Signals - newser.com
Belite Bio stock reaches all-time high at 92.12 USD By Investing.com - Investing.com Nigeria
Belite Bio stock reaches all-time high at 92.12 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Should You Buy? - Defense World
Is Belite Bio Inc Depositary Receipt stock a safe investment in uncertain markets2025 Market WrapUp & Technical Pattern Based Buy Signals - nchmf.gov.vn
Belite Bio stock rating reiterated at Buy by H.C. Wainwright - Investing.com South Africa
Belite Bio (NASDAQ:BLTE) Trading Up 6.7%Should You Buy? - MarketBeat
(BLTE) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Belite Bio stock hits all-time high at 86.61 USD By Investing.com - Investing.com Philippines
Belite Bio to Participate in the 2025 Maxim Growth Summit - markets.businessinsider.com
Belite Bio stock hits all-time high at 86.61 USD - Investing.com
Belite Bio Stocks Surge Amid Drug Approval Hopes - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Consensus Target Price from Brokerages - Defense World
Eagle Point Credit Company Inc. (NYSE:ECC) Receives $8.21 Average Price Target from Analysts - Defense World
Oct. 22, 2025: Belite Bio to Participate in Maxim Growth Summit; meetings available via Maxim rep - Stock Titan
Phase 3 interim prompts China NMPA Priority NDA Review — Belite Bio's Tinlarebant; topline Q4 2025 - Stock Titan
Cango Inc. to Terminate ADR Program and List Class A Ordinary Shares Directly on NYSE - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - Yahoo Finance
Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI) - The Globe and Mail
What MACD signals say about Belite Bio Inc Depositary Receipt2025 Top Gainers & Real-Time Market Trend Scan - newser.com
GAMMA Investing LLC Trims Stock Holdings in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
3 Lesser-Known Healthcare Names With Major Upside in Store - Investing.com
3 Lesser-Known Healthcare Names With Major Upside in Store - MarketBeat
Volume spikes in Belite Bio Inc Depositary Receipt stock – what they mean2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Juvenile Macular Degeneration Pipeline 2025: Innovative Clinical Developments by 80+ Global Leaders – DelveInsight | Highlighting Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen - Barchart.com
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeHere's Why - MarketBeat
Belite Bio (NASDAQ:BLTE) Upgraded at Wall Street Zen - MarketBeat
Stargardt Disease Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Belite Bio (NASDAQ:BLTE) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
Analysts Set Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) PT at $96.00 - MarketBeat
HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives $96.00 Average Target Price from Analysts - Defense World
Lin BioScience Subsidiary Belite Completes LBS-008 STGD1 Phase III Trial, Secures NT$8.4 Billion Private Placement - 全球醫療採購網
HC Wainwright Has Lowered Expectations for Belite Bio (NASDAQ:BLTE) Stock Price - MarketBeat
ASICS Corporation Unsponsored ADR (ASCCY) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.21%
자본화:
|
볼륨(24시간):